Literature DB >> 28599951

Age, gender, and percentage of circulating osteoprogenitor (COP) cells: The COP Study.

Piumali Gunawardene1, Ahmed Al Saedi2, Lakshman Singh3, Sandra Bermeo4, Sara Vogrin5, Steven Phu6, Pushpa Suriyaarachchi7, Robert J Pignolo8, Gustavo Duque9.   

Abstract

Circulating osteoprogenitor (COP) cells are blood-borne cells which express a variety of osteoblastic markers and are able to form bone nodules in vivo. Whereas a high percentage of COP cells (%COP) is associated with vascular calcification, low %COP has been associated with disability and frailty. However, the reference range of %COP in age- and gender-matching populations, and the age-related changes in %COP remain unknown. A cross-sectional study was undertaken in 144 healthy volunteers in Western Sydney (20-90year-old, 10 male and 10 female subjects per decade). %COP was quantified by flow cytometry. A high inter-and intra-rater reliability was found. In average, in this healthy population average of %COP was 0.42. There was no significant difference in %COP among the age groups. Similarly, no significant difference was found in %COP with gender, weight, height or BMI. In addition, we identified a normal reference range of %COP of 0.1-3.8%. In conclusion, in addition to the identification of steady levels of COP cells with age, we also identified a normal reference range of %COP, which could be used in future studies looking at musculoskeletal diseases in older populations.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Circulating osteoprogenitors; Musculoskeletal; Osteosarcopenia; Stem cells

Mesh:

Year:  2017        PMID: 28599951     DOI: 10.1016/j.exger.2017.06.004

Source DB:  PubMed          Journal:  Exp Gerontol        ISSN: 0531-5565            Impact factor:   4.032


  10 in total

Review 1.  One of the Primary Functions of Tissue-Resident Pluripotent Pericytes Cells May Be to Regulate Normal Organ Growth and Maturation: Implications for Attempts to Repair Tissues Later in Life.

Authors:  David A Hart
Journal:  Int J Mol Sci       Date:  2022-05-14       Impact factor: 6.208

Review 2.  Osteosarcopenia: A Narrative Review on Clinical Studies.

Authors:  Angela Polito; Lorenzo Barnaba; Donatella Ciarapica; Elena Azzini
Journal:  Int J Mol Sci       Date:  2022-05-17       Impact factor: 6.208

3.  Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network.

Authors:  Gordon Cook; Alessandra Larocca; Thierry Facon; Sonja Zweegman; Monika Engelhardt
Journal:  Leukemia       Date:  2020-06-18       Impact factor: 11.528

Review 4.  Circulating osteogenic precursor cells: Building bone from blood.

Authors:  Jack Feehan; Kulmira Nurgali; Vasso Apostolopoulos; Ahmed Al Saedi; Gustavo Duque
Journal:  EBioMedicine       Date:  2018-12-03       Impact factor: 8.143

Review 5.  Current and emerging biomarkers of frailty in the elderly.

Authors:  Ahmed Al Saedi; Jack Feehan; Steven Phu; Gustavo Duque
Journal:  Clin Interv Aging       Date:  2019-02-19       Impact factor: 4.458

Review 6.  Neuropsychiatric Disorders and Frailty in Older Adults over the Spectrum of Cancer: A Narrative Review.

Authors:  Mariya Muzyka; Luca Tagliafico; Gianluca Serafini; Ilaria Baiardini; Fulvio Braido; Alessio Nencioni; Fiammetta Monacelli
Journal:  Cancers (Basel)       Date:  2022-01-05       Impact factor: 6.639

7.  Circulating Osteogenic Progenitor Cells Enhanced with Teriparatide or Denosumab Treatment.

Authors:  Mercè Giner; María Angeles Vázquez-Gámez; María José Miranda; Jesús Bocio-Nuñez; Francisco Jesús Olmo-Montes; Miguel Angel Rico; Miguel Angel Colmenero; María-José Montoya-García
Journal:  J Clin Med       Date:  2022-08-14       Impact factor: 4.964

8.  Circulating osteogenic progenitors and osteoclast precursors are associated with long-term glycemic control, sex steroids, and visceral adipose tissue in men with type 2 diabetes mellitus.

Authors:  Elliot Ballato; Fnu Deepika; Mia Prado; Vittoria Russo; Virginia Fuenmayor; Siresha Bathina; Dennis T Villareal; Clifford Qualls; Reina Armamento-Villareal
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-12       Impact factor: 6.055

Review 9.  The Blood Circulating Rare Cell Population. What is it and What is it Good For?

Authors:  Stefan Schreier; Wannapong Triampo
Journal:  Cells       Date:  2020-03-25       Impact factor: 6.600

10.  Increase in bone metabolic markers and circulating osteoblast-lineage cells after orthognathic surgery.

Authors:  Yoko Abe; Mirei Chiba; Sanicha Yaklai; Roan Solis Pechayco; Hikari Suzuki; Tetsu Takahashi
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.